American Diabetes Association

The ACHIEVE-5 trial demonstrated that adding oral orforglipron (Foundayo) to basal insulin improved glycemic control and reduced body weight in diabetes patients. The results were presented at the American Diabetes Association annual meeting.

2-year results from the SUPPRESS-EARLY trial indicate that early use of tirzepatide (Mounjaro, Zepbound) in type 2 diabetes management significantly improves outcomes. The findings were presented at the American Diabetes Association annual meeting.

Updated phase II data from the VESPER program showed that patients achieved weight loss with weekly doses of the investigational GLP-1 agonist berobenatide. The study, presented at the American Diabetes Association annual meeting, is exploring whether monthly dosing can maintain these results.

Steven Kahn, editor-in-chief of Diabetes Care, was removed from an American Diabetes Association meeting after distributing materials. He stated the ADA's actions prompted millions to consider the issue.

The American Diabetes Association's CEO apologized to a Northwestern researcher and other experts who were removed from a conference for distributing an editorial critical of President Trump's administration. The incident occurred during a conference in New Orleans, where security and police escorted the group out, and the association has pledged an independent review.

The American Diabetes Association expelled conference participants for distributing an editorial critical of Trump administration's scientific research cuts, leading to resignations. The article also mentions the Department of Defense reducing recognized religious affiliations, attributed to Trump's influence.

Five diabetes experts were expelled from the American Diabetes Association meeting in New Orleans for distributing paper copies of an editorial, leading to threats of arrest. The ADA issued a formal apology after backlash but faced criticism over the incident's implications for biomedical research under the second Trump administration.

The American Diabetes Association's CEO apologized to five expelled members who were removed for distributing an editorial criticizing federal research cuts. The apology acknowledged the hurt caused and pledged to rebuild trust within the diabetes community.

Five diabetes experts were expelled from the American Diabetes Association annual meeting in New Orleans for distributing an editorial criticizing federal cuts to biomedical research. The incident has sparked backlash in the diabetes research and practice community, with the ADA's communications further worsening the situation.

California's Senate passed a bill requiring health insurers to cover GLP-1 weight-loss drugs like Ozempic for public employees, but CalPERS opposes it due to projected $437 million premium increases and $187 million state fund costs. Sen. Laura Richardson advocates for a five-year pilot program to cover chronic weight management treatments, citing potential long-term savings from reduced healthcare costs.

A Northwestern researcher and four others were removed from an American Diabetes Association conference for distributing an editorial critical of President Trump's attacks on scientific research. The group faced police intervention and had their materials confiscated, with the association citing code of conduct violations.

AstraZeneca's investigational GLP-1 pill, elecoglipron, demonstrated significant weight loss in a Phase 2 obesity trial (11.2% after 36 weeks) and improved blood sugar control in a diabetes trial (1.74 percentage-point A1C reduction). Results were compared to oral Ozempic, which showed a smaller A1C decrease in the same study.

The article discusses updates on competition in obesity drugs, insights on eating disorders, new information on a BCG vaccine, and a clarification from the American Diabetes Association regarding a police incident. It is part of STAT’s coverage from the ADA annual conference.

The American Diabetes Association annual conference highlights new diabetes treatments, including triple hormone receptors and a monthly obesity drug. The article summarizes key developments from the event.

Five scientists were ejected from the American Diabetes Association conference for distributing an editorial criticizing the Trump administration's attacks on scientific research. The editorial, published in Diabetes Care, was handed out outside a session where an NIH director was scheduled to speak, though the director later canceled and another official spoke instead.

Eli Lilly's next-generation obesity drug, retatrutide, demonstrated significant weight loss and blood sugar reduction in a study, but new data revealed seven cases of arrhythmias and three major cardiovascular complications among 403 participants. The findings were presented at the American Diabetes Association meeting and published in the Lancet.

Pfizer's obesity drug berobenatide, acquired from Metsera, showed continued weight loss when transitioning from weekly to monthly dosing in a mid-stage study. Patients lost up to 12.1% of their weight by 28 weeks, but the rate lagged behind Eli Lilly's Zepbound trial results.

The article covers highlights from the American Diabetes Association's annual conference in New Orleans, including a keynote speech by Rick Woychik, a senior adviser to NIH chief Jay Bhattacharya, and discussions on newer GLP-1 drugs, research funding cuts, and a protest. The piece also mentions STAT+ content and invites readers to engage with the newsletter.

Members of the American Diabetes Association were escorted out of a New Orleans convention center by police during their annual meeting while distributing an editorial. The incident occurred as they handed out copies of the editorial.

The Texas Attorney General is investigating energy drinks. The American Diabetes Association's annual conference is starting in New Orleans, with STAT providing coverage through its newsletters.

Dr. Ken Berry, a Tennessee physician, claims he lost 70 pounds and reversed prediabetes by adopting a carnivore diet, citing growing interest in high-protein diets among Americans. A 2025 survey showed 'good source of protein' became the top criterion for healthy food, with 70% of Americans prioritizing protein intake. Nutrition experts debate the long-term health impacts of carnivore diets, which exclude plant-based foods.

Diabetes detection requires better tools to catch the disease early, as blood glucose levels may not be enough in some populations. New tools are being developed to improve diabetes detection. This development aims to enhance early detection and treatment of diabetes.